The UNC Center for Functional GI and Motility Disorders is currently conducting a Phase III drug trial to investigate the long-term efficacy of Rifaximin for the treatment of IBS-D symptoms.
Rifaximin is a non-absorbed antibiotic currently approved by the FDA for the treatment of Traveler’s Diarrhea and Hepatic Encephalopathy. Previous studies have shown significant improvement of symptoms with Rifaximin treatment in subjects with IBS-D.
- At least 18 years of age
- Diagnosed with IBS-D or have experienced the symptoms (abdominal pain, bloating, and diarrhea) at least 3 days per month over the last 3 months.
- No history of inflammatory bowel disorders
- Colonoscopy with biopsy within the last 10 years or willing to undergo colonoscopy or sigmoidoscopy for the study.
The study will consist of four treatment phases and two maintenance phases (after Treatment Phase 2 and Treatment Phase 3) over the course of up to 46 weeks. Participants will be determined responders or non-responders to the study medication at the completion of Treatment Phase 2 (8 weeks). Only responders will be eligible to complete the remainder of the study.
Eligible participants will be asked to complete up to 9 visits during which vital measurements will be taken along with blood, urine, and stool samples. In addition, participants will be asked to keep a daily log of their symptoms over the course of the study.
Eligible participants may receive study-related care at no cost, study medication, colonoscopy at no cost (if applicable), and up to $2000 in compensation.
Call or email Daniel Temas at 919-843-1003 or email@example.com to find out more information about participation.
To find more information, please visit the Salix website here.